Dr. Soliman Abdel Kader Fakeeh Hospital Company

SASE:4017 Stock Report

Market Cap: ر.س8.1b

Dr. Soliman Abdel Kader Fakeeh Hospital Valuation

Is 4017 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4017 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 4017 (SAR35.16) is trading above our estimate of future cash flow value (SAR2.43)

Significantly Below Future Cash Flow Value: 4017 is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4017?

Key metric: As 4017 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4017. This is calculated by dividing 4017's market cap by their current earnings.
What is 4017's PE Ratio?
PE Ratio34.8x
Earningsر.س232.20m
Market Capر.س8.09b

Price to Earnings Ratio vs Peers

How does 4017's PE Ratio compare to its peers?

The above table shows the PE ratio for 4017 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.2x
4004 Dallah Healthcare
23x17.92%ر.س10.2b
4005 National Medical Care
18.7x8.95%ر.س5.6b
4002 Mouwasat Medical Services
15.1x4.90%ر.س12.9b
4018 Almoosa Health
31.9x28.16%ر.س5.2b
4017 Dr. Soliman Abdel Kader Fakeeh Hospital
34.8x2.35%ر.س8.1b

Price-To-Earnings vs Peers: 4017 is expensive based on its Price-To-Earnings Ratio (34.8x) compared to the peer average (22.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 4017's PE Ratio compare vs other companies in the SA Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4017 34.8xIndustry Avg. 21.4xNo. of Companies4PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4017 is expensive based on its Price-To-Earnings Ratio (34.8x) compared to the SA Healthcare industry average (21.4x).

Price to Earnings Ratio vs Fair Ratio

What is 4017's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4017 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.8x
Fair PE Ratio17.1x

Price-To-Earnings vs Fair Ratio: 4017 is expensive based on its Price-To-Earnings Ratio (34.8x) compared to the estimated Fair Price-To-Earnings Ratio (17.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4017 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س35.16
ر.س40.90
+16.33%
5.44%ر.س44.10ر.س38.00n/a4
Aug ’27ر.س34.94
ر.س40.90
+17.06%
5.44%ر.س44.10ر.س38.00n/a4
Jul ’27ر.س36.76
ر.س40.28
+9.56%
5.76%ر.س44.10ر.س38.00n/a4
Jun ’27ر.س35.72
ر.س42.02
+17.64%
6.93%ر.س45.00ر.س38.00n/a5
May ’27ر.س36.34
ر.س42.02
+15.63%
6.93%ر.س45.00ر.س38.00n/a5
Apr ’27ر.س34.50
ر.س42.72
+23.83%
4.92%ر.س45.00ر.س39.50n/a5
Mar ’27ر.س29.00
ر.س42.72
+47.31%
4.92%ر.س45.00ر.س39.50n/a5
Feb ’27ر.س35.30
ر.س43.74
+23.91%
3.24%ر.س45.00ر.س41.00n/a5
Jan ’27ر.س34.40
ر.س43.74
+27.15%
3.24%ر.س45.00ر.س41.00n/a5
Dec ’26ر.س37.02
ر.س44.14
+19.23%
1.53%ر.س45.00ر.س43.00n/a5
Nov ’26ر.س42.32
ر.س44.18
+4.38%
1.70%ر.س45.00ر.س43.00n/a4
Oct ’26ر.س41.32
ر.س46.94
+13.60%
11.87%ر.س58.00ر.س43.00n/a5
Sep ’26ر.س39.46
ر.س45.28
+14.76%
13.89%ر.س58.00ر.س37.00n/a6
Aug ’26ر.س38.70
ر.س48.45
+25.19%
17.91%ر.س62.00ر.س37.00ر.س34.946
Jul ’26ر.س39.98
ر.س48.45
+21.19%
17.91%ر.س62.00ر.س37.00ر.س36.766
Jun ’26ر.س40.90
ر.س52.82
+29.14%
13.47%ر.س62.00ر.س44.10ر.س35.725
May ’26ر.س45.65
ر.س60.22
+31.92%
5.74%ر.س65.10ر.س55.00ر.س36.345
Apr ’26ر.س49.60
ر.س62.52
+26.04%
8.71%ر.س72.00ر.س55.00ر.س34.506
Mar ’26ر.س62.30
ر.س63.80
+2.41%
8.05%ر.س72.00ر.س55.00ر.س29.006
Feb ’26ر.س68.20
ر.س62.97
-7.67%
10.60%ر.س72.00ر.س50.00ر.س35.306
Jan ’26ر.س67.50
ر.س62.97
-6.72%
10.60%ر.س72.00ر.س50.00ر.س34.406
Dec ’25ر.س63.20
ر.س61.97
-1.95%
9.05%ر.س66.00ر.س50.00ر.س37.026
Nov ’25ر.س57.80
ر.س61.97
+7.21%
9.05%ر.س66.00ر.س50.00ر.س42.326
Oct ’25ر.س59.10
ر.س61.97
+4.85%
9.05%ر.س66.00ر.س50.00ر.س41.326
Sep ’25ر.س58.00
ر.س64.36
+10.97%
2.86%ر.س66.00ر.س61.00ر.س39.465
Aug ’25ر.س59.40
ر.س64.36
+8.35%
2.86%ر.س66.00ر.س61.00ر.س38.705
ر.س40.9
Fair Value
14.0% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/22 22:43
End of Day Share Price 2026/08/20 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dr. Soliman Abdel Kader Fakeeh Hospital Company is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jassim Al-JubranAljazira Capital Company
Marina MikhailCI Capital Research
Ahmed MoatazEFG-Hermes Research